Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ublituximab Clear all
Terminated Phase 2 Interventional Results available

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

NCT03828448
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Long Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

NCT07103746
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Ublituximab, Placebo for Ublituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Active, not recruiting Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
22
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

NCT06143514
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
No intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Francisco, California • Smyrna, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Not applicable Interventional

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

NCT06864936
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab, Other disease modifying therapies
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

NCT01744912
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Ublituximab, Lenalidomide
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Huntsville, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

An Extension of the TG1101-RMS201 Trial

NCT03381170
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

NCT07680946
View directory record Official record
Conditions
Schizophrenia
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional

Ublituximab + Ibrutinib in Select B-cell Malignancies

NCT02013128
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Ublituximab, Ibrutinib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
18
States / cities
Huntsville, Alabama • Tucson, Arizona • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04806035
View directory record Official record
Conditions
CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL
Interventions
TG-1801, Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
TGR-1202, TGR-1202 + Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

NCT03778073
View directory record Official record
Conditions
B-cell Non Hodgkin Lymphoma, Richter's Transformation
Interventions
Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 6, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

NCT02612311
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ublituximab, TGR-1202, Chlorambucil
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 6, 2026, 5:01 PM EDT
Recruiting Early Phase 1 Interventional

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

NCT06629428
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 6, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

NCT02535286
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Umbralisib, ublituximab, TG-1501
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 6, 2026, 5:01 PM EDT